Inhibikase Therapeutics Inc President & CEO Milton Werner sat down with Proactive Investors at the ThinkEquity Conference in New York. The Atlanta-based, privately-held pharma company is focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the treatment of neurological infections and neurodegenerative diseases.
Inhibikase Therapeutics receives clinical clearance from FDA on its Parkinson's disease therapy
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE